An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: Phosphodiesterases and drug selectivity

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 27, Issue 2, 2005, Pages 101-118

  Gupta, Ranju ^a   Kumar, G ^a   Kumar, R Sunil ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

CAMP; CGMP; Cyclic nucleotide phosphodiesterases; PDE inhibitors; PDE selectivity

Indexed keywords

2 AMINO 4,5 DIHYDRO 6 METHYL 5 OXO 4 PROPYL 1,2,4 TRIAZOLO[1,5 A]PYRIMIDINE; 3 (3 CYCLOPENTYLOXY 4 METHOXYBENZYL) 6 ETHYLAMINO 8 ISOPROPYL 3H PURINE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; 4,5 DIHYDRO 6 [4 (1H IMIDAZOL 1 YL)PHENYL] 5 METHYL 3(2H) PYRIDAZINONE; 6 BROMO 8 METHYLAMINOIMIDAZO[1,2 A]PYRAZINE 2 CARBONITRILE; ACEFYLLINE; AMRINONE; AROPHYLLINE; B 9004070; BAMIFYLLINE; CAFFEINE; CATECHOL ETHER; CHLORPROMAZINE; CILOMILAST; CIPAMPHYLLINE; CP 77059; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITOR; DENBUPHYLLINE; DIPROPHYLLINE; DIPYRIDAMOLE; DOXOFYLLINE; EMD 54662; ENOXIMONE; ETIOPHYLLINE; FR 226807; IBUDILAST; ISOBUTYLMETHYLXANTHINE; ISOENZYME; LAPRAPHYLLINE; METHYLXANTHINE; MILRINONE; N HYDROXY 5,6 DIMETHOXY 2 BENZO[B]THIOPHENECARBOXIMIDAMIDE; NITRAQUAZONE; PAPAVERINE; PENTOXIFYLLINE; PHOSPHODIESTERASE 1 INHIBITOR; PHOSPHODIESTERASE 10; PHOSPHODIESTERASE 11; PHOSPHODIESTERASE 2 INHIBITOR; PHOSPHODIESTERASE 9; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE VI; PHOSPHODIESTERASE VII; PHOSPHODIESTERASE VIII; PICLAMILAST; PIMOBENDAN; PIMOZIDE; PIPERANOMETOZINE; PROXYPHYLLINE; QUINAZOLINEDIONE; ROLIPRAM; RS 14203; RS 25344; SDZ MKS 492; SIGUAZODAN; SILDENAFIL; SPLEEN EXONUCLEASE; SULMAZOLE; TADALAFIL; THEOBROMINE; THEOPHYLLINE; THEOPHYLLINE DERIVATIVE; TIBENELAST; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; VARDENAFIL; VEROPHYLLINE; VINPOCETINE; XANTHINE DERIVATIVE; ZAPRINAST; ZORDAVERINE;

CHEMICAL STRUCTURE; DRUG ACTIVITY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW;

CYCLIC AMP; CYCLIC GMP; DRUG DESIGN; ISOENZYMES; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES;

EID: 17044379460     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2005.27.2.876285     Document Type: Review

References (88)

1. Torphy, TJ., Page, C. Phosphodiesterases: The journey towards therapeutics. Trends Pharmacol Sci 2000, 21: 157-9.
2. Torphy, T.J., Livi, G.P., Christensen, S.B. Novel phosphodiesterase inhibitors for the therapy of asthma. Drug News Perspect 1993, 6(4): 203-13.
3. Connor, D.T., Unangst, P.C. Antiallergic agents. In: Burger's Medicinal Chemistry and Drug Discovery. Wolff, M.E. (Ed.). John Wiley and Sons, Inc.: New York 1996, 535-43.
4. Piaz, V.D., Giovannoni, M.P. Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies. Eur J Med Chem 2000, 35: 463-80.
5. Beavo, J.A. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 1995, 75(4): 725-48.
6. Harvey, W. PDE inhibitors: Drugs with an expanding range of therapeutic uses. Research Conferences, Nice, France 1999, 1-3.
7. Francis, S.H., Turko, I.V., Corbin, J.D. Cyclic nucleotide phosphodiesterases: Relating structure and function. Prog Nucleic Acid Res Mol Biol 2001, 65: 1-52.
8. Conti, M., Jin, S.L.C. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 2000, 63: 1-38.
9. Raeburn, D., Karlsson, J.-A. Phosphodiesterase inhibitors: Knockout drops? J Pharm Pharmacol 1997, 49(Suppl. 3): 19-24.
10. Teixeira, M.M., Gristwood, R.W., Cooper, N., Hellewell, P.G. Phosphodiesterase (PDE) 4 inhibitors: Anti-inflammatory drugs of the future? Trends Pharmacol Sci 1997, 18: 164-70.
11. Soderling, S.H., Beavo, J. A. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions. Curr Opin Cell Biol 2000, 12: 174-9.
12. Beavo, J.A., Reifsnyder, D.H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 1990, 11: 150-6.
13. Wang, J.H., Sharma, R.K., Mooibroek, M.J. Calmodulin stimulated cyclic nucleotide phosphodiesterases. In: Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action. Beavo, J., Houslay, M.D. (Eds.). John Wiley and Sons: Chichester, UK 1990, 19-60.
14. Kincaid, R.L., Balaban, C.D., Billingsley, M.L. Regional and developmental expression of calmodulin-dependent cyclic nucleotide phosphodiesterase in rat brain. Adv Second Messenger Phosphoprotein Res 1992, 25: 111-22.
15. Yan, C., Beavo, J.A. Molecular cloning and cellular distribution of the 75-kDa calmodulin-dependent phosphodiesterase (abstract). FASEB J 1994, 8: A81.
16. Yang, Q., Paskind, M., Bolger, G. et al. A novel cyclic GMP stimulated phosphodiesterase from rat brain. Biochem Biophys Res Commun 1994, 205: 1850-8.
17. Lugnier, C., Muller, B., Le, B.A., Beaudry, C., Rousseau, E. Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions. J Pharmacol Exp Ther 1993, 265: 1142-51.
18. Whalin, M.E., Scammell, J.G., Strada, S.J., Thompson, W.J. Phosphodiesterase II, the cGMP-activatable cyclic nucleotide phosphodiesterase, regulates cAMP metabolism in PC12 cells. Mol Pharmacol 1991, 39: 711-7.
19. Taira, M., Hockman, S.C., Calvo, J.C., Belfrage, P., Manganiello, V.C. Molecular cloning of the rat adipocyte hormone-sensitive cyclic GMP-inhibited cyclic nucleotide phosphodiesterase. J Biol Chem 1993, 268: 18573-9.
20. Reeves, M.L., England, P.J. Cardiac phosphodiesterases and the functional effects of selective inhibition. In: Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action. Beavo, J.A., Houslay, M.D. (Eds.). Wiley: Chichester, UK 1990, 299-316.
21. Houslay, M.D., Sullivan, M., Bolger, G.B. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: Intracellular targeting, regulation, and selective inhibition by compounds exerting antiinflammatory and anti- depressant actions. Adv Pharmacol 1998, 44: 225-342.
22. Crocker, I.C., Townley, R.G. Therapeutic potential of phosphodiesterase4 inhibitors in allergic diseases. Drugs Today 1999, 35(7): 519-35.
23. Barnette, M.S. Phosphodiesterase4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog Drug Res 1999, 53: 195-229.
24. Francis, S.H., Thomas, M.K., Corbin, J.D. Cyclic GMP-binding cyclic GMP-specific phosphodiesterase from lung. In: Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action. Beavo, J., Houslay, M.D. (Eds.). John Wiley and Sons: Chichester, UK 1990, 117-40.
25. Burns, F., Rodger, I.W., Pyne, N.J. The catalytic subunits of protein kinase A triggers activation of the type V cyclic GMP-specific phosphodiesterase from guinea pig lung. J Biochem 1992, 283: 487-91.
26. Deterre, P., Bigay, J., Forquet, F., Robert, M., Chabre, M. cGMP phosphodiesterase of retinal rods is regulated by two inhibitory subunits. Proc Natl Acad Sci U S A 1988, 85: 2424-8.
27. Fisher, D.A., Smith, J.F., Pillar, J.S., St. Denis, S.H., Cheng, J.B. Isolation and characterization of PDE 8A, a novel human cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 1998, 246(3): 570-7.
28. Fisher, D.A., Smith, J.F., Pillar, J.S., Cheng, J.B. Isolation and characterization of PDE 9A, a novel human cGMP specific phosphodiesterase. J Biol Chem 1998, 273(25): 15559-64.
29. Soderling, S.H., Bayuga, S.J., Beavo, J.A. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE 10A. Proc Natl Acad Sci U S A 1999, 96(12): 7071-6.
30. Yuasa, K., Ohgaru, T., Asahina, M., Omori, K. Identification of rat cyclic nucleotide phosphodiesterase (PDE 11A): Comparison of rat and human PDE 11A splice variants. Eur J Biochem 2001, 268(16): 4440-8.
31. Wisher, R.E., Cain, M.H., Bristol, J.A. A new generation of phosphodiesterase inhibitors: Multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem 1985, 28: 537-45.
32. Lugnier, C., Schoeffter, P., Le, B.A., Strouthou, E., Stoclet, J.C. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 1986, 35: 1743-51.
33. Palfreyman, M.N., Souness, J.E. Phosphodiesterase type IV inhibitors. In: Progress in Medicinal Chemistry, Vol. 33. Ellis, G.P., Luscombe, D.K. (Eds.). Elsevier: Amsterdam 1996, 1-52.
34. Fournier, Leclerc, P., Cormier, N., Bailey, J.L. Implication of calmodulin dependent phosphodiesterase type1 during bovine sperm capacitation. J Androl 2003, 24(1), 104-12.
35. Wu, S.N., Li, H.F., Chiang, H.T. Vinpocetine-induced stimulation of calcium-activated potassium currents in rat pituitary GH3 cells. Biochem Pharmacol 2001, 61: 877-92.
36. Podzuweit, T., Nennstiel, P., Muller, A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3- nonyl) adenine. Cellular Signal 1995, 7: 733-8.
37. Foster, R.W., Jubber, A.S., Hassan, N.A. et al. Trials of the bronchodilator activity of the xanthine analogue SDZ MKS 492 in healthy volunteers during a methacholine challenge test. Eur J Clin Pharmacol 1993, 45: 227-34.
38. Alousi, A.A., Canter, J.M., Montenaro, M., Fort, D.J., Ferrari, R.A. Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals. J Cardiovasc Pharmacol 1983, 5: 792-803.
39. Marivet, M.C., Bourguignon, J.J., Lugnier, C., Mann, A., Stoclet, J.C., Wermuth, C.G. Inhibition of cyclic adenosine-3′,5′-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. J Med Chem 1989, 32: 1450-7.
40. Gupta, R., Gandhi, D., Jindal, D.P. Selective phosphodiesterase 4 inhibitors-emerging trends in asthma therapy (Antiasthmatics-3). J Sci Indust Res 2003, 62: 537-53.
41. Robichaud, A., Stamatiou, P.B., Catherine Jin, S.-L. et al. Deletion of phosphodiesterase 4D in mice shortens alpha2-adenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002, 110: 1045-52.
42. He, W., Huang, F.-C., Hanney, B. et al. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors. J Med Chem 1998, 41: 4216-23.
43. Bacher, E., Boer, C., Bray-French, K. et al. N-aryl rolipram derivatives as potent and selective PDE 4 inhibitors. Bioorg Med Chem Lett 1998, 8: 3229-34.
44. Christensen, S.B., Torphy, T.J. Isozyme-selective phosphodiesterase inhibitors as antiasthmatic agents. Ann Rep Med Chem 1994, 29: 185-94.
45. Silvestre, J., Graul, A., Castaner, J. SB-207499, antiasthmatic/anti- inflammatory phosphodiesterase 4 inhibitors. Drug Future 1998, 23: 607-15.
46. Gamble, E., Grootendorst, D.C., Brightling, C.E. et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 168(8): 976-82.
47. Van der Mey, M., Hatzelmann, A., Van der Laan, I.J., Sterk, G.J., Thibaut, U., Timmerman, H. Novel selective PDE4 inhibitors, 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4- dimethoxyphenyl)-2H-phthalazin-1-ones and analogues. J Med Chem 2001, 44: 2511-22.
48. 3H]rolipram. J Pharmacol Exp Ther 2003, 305(2): 565-72.
49. Harbinson, P.L., Macleod, D., Hawksworth, R. et al. The effect of a novel orally active selective PDE 4 iso-enzyme inhibitor (CDP840) on allergen induced responses in asthmatic subjects. Eur Respir J 1997, 10: 1008-14.
50. Wilhelm, R.S., Fatherlec, P.R., Chin, R.L. Preparation of 6,8-disubstituted quinoline phosphodiesterase 4 inhibitors. Int Pat Appl WO 94 22852 (Chem Abstr 1995, 122: 55901).
51. Piaz, V.D., Giovannoni, M.P., Castellana, C. et al. Heterocyclicfused 3[2H]- pyridazinones as potent and selective phosphodiesterase 4 inhibitors: Further structure-activity relationships and molecular modeling studies. Eur J Med Chem 1998, 33: 789-97.
52. Shimazaki, N., Sawada, A., Watanabe, S. Preparation of pyrido[2,3- b]pyrazines as inhibitors of phosphodiesterase 4 and tumor necrosis factor production. Int Pat Appl WO 97 24355 (Chem Abstr 1997, 127: 149156).
53. Dyke, H.J., Montana, J.G., Lowe, C., Kendall, H.J., Hamnah, J., Sabin, V.M. Preparations of benzofuran carhoxamides as phosphodiesterase 4 or TNF inhibitors. Int Pat Appl WO 97 44036 (Chem Abstr 1998, 128: 48146).
54. Crespo, M.I., Pages, L., Vega, A. et al. Design, synthesis and biological activities of new thieno[3,2-d]pyrimidines as selective type 4 phosphodiesterase Inhibitors. J Med Chem 1998, 41: 4021-35.
55. Trifilieff, A., Wyss, D., Walker, C., Mazzoni, L., Hersperger, R. Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-[8-benzo (1,2,5) oxadiazol-5-yl-(1,7) naphthyridin-6-yl] benzoic acid (NVP-ABE 171), a 1,7 naphthyridine derivative, with antiinflammatory activities. J Pharmacol Exp Ther 2002, 301: 241-8.
56. Macdonald, D., Perrier, H., Liu, S. et al. Hunting the emesis and efficacy targets of PDE 4 inhibitors: Identification of the photoaffinity probe 8-(3-azidophenyl)-6-[(4-iodo-1H-1-imidazolyl) methyl] quinoline (APIIMQ). J Med Chem 2000, 43: 3820-3.
57. Jindal, D.P., Bhatti, R.S., Ahlawat, S., Gupta, R. Synthesis and bronchodilatory activity of some nitrogen bridgehead compounds. Eur J Med Chem 2002, 37: 419-25.
58. Nielforth, K.A., Gianutsos, G. Central nervous system stimulants. In: Principles of Medicinal Chemistry. Foye, W.O., Lemke, T.L., Williams, D.A. (Eds.). B.I. Waverly Pvt. Ltd.: New Delhi 1995, 275-6.
59. Miyamoto, K., Kurita, M., Ohmae, S., Sakai, R., Sanae, F., Takagi, K. Selective tracheal relaxation and phosphodiesterase-4 inhibition by xanthine derivatives. Eur J Pharmacol 1994, 267(3): 317-22.
60. Wells, J.N., Garst, J.E., Kramer, G.L. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from pig coronary arteries by 1,3 disubstituted and 1,3,8 trisubstituted xanthines. J Med Chem 1981, 24: 954-8.
61. Nicholson, C.D., Jackman, S.A., Wilke, R. The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re-uptake site. Br J Pharmacol 1989, 97: 889-97.
62. Buckle, D.R., Arch J.R.S., Connolly, B.J. et al. Inhibition of cyclic nucleotide phosphodiesterase by derivatives of 1,3-bis(cyclopropylmethyl) xanthine. J Med Chem 1994, 37: 476-85.
63. 2B-selective adenosine receptor antagonists. J Med Chem 2002, 45: 1500-10.
64. Kawasaki, A., Hoshino, K., Osaki, R., Mizushima, Y., Yano, S. Effect of ibudilast: A novel antiasthmatic agent, on airway hypersensitivity in bronchial asthma. J Asthma 1992, 29: 245-52.
65. Davies, G.E. Antibronchoconstriction activity of two new phosphodiesterase inhibitors, a triazolopyrazine (ICI 58301) and triazolopyrimidine (ICI 63197). J Pharm Pharmacol 1973, 25: 681-9.
66. Cortijo, J., Pons, R., Dasi, F. et al. Bronchodilator and antiinflammatory activities of SCA 40: Studies in human isolated bronchus, human eosinophils and in the guinea pig in vivo. Naunyn Schmiedebergs Arch Pharmakol 1997, 356: 806-14.
67. Cavalla, D., Gale, D. A case history of successful virtual research. Drug News Perspect 1997, 10: 470.
68. Norman, P. PDE 4 inhibitors. Exp Opin Ther Pat 1998, 8: 771.
69. Amschler, H., Beer, T., Gutterer, B. et al. Phenyl dihydrobenzofurans. Int Pat Appl WO 96 36625 (Chem Abstr 1997, 126: 74737).
70. Duplantier, A.J., Andresen, C.J., Cheng, J.B. et al. 7-oxo-4,5,6,7- letrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase. J Med Chem 1998, 41: 2268-71.
71. Kuss, H., Hofgen, N., Egerland, U. et al. AWD 12-281, antiasthmatic/antiinflammatory phosphodiesterase 4 inhibitor. Drugs Future 2002, 27(2): 111-6.
72. Raboisson, P., Lugnier, C., Muller, C. et al. Design, synthesis and structure-activity relationships of a series of 9-substituted adenine derivatives as selective phosphodiesterase type-4 inhibitors. Eur J Med Chem 2003, 38: 199-214.
73. Bourguignon, J.-J., Desaubry, L., Raboisson, P., Wermuth, C.-G., Lugnier. C. 9-Benzyladenines: Potent and selective cAMP phosphodiesterase inhibitors. J Med Chem 1997, 40: 1768-70.
74. Giembycz, M.A. Phosphodiesterase 4 inhibitors and the treatment of asthma. Where are we now and where do we go from here? Drugs 2000, 59: 193-212.
75. Ko, W.-C., Chen, M.-C, Wang, S.-H., Lai, Y.-H., Chen, J.-H., Lin, C.-N. 3-0-Methylquercetin more selectively inhibits phosphodiesterase subtype 3. Planta Med 2003, 69: 310-5.
76. Rotella, D.P. Phosphodiesterase 5 inhibitors: Current status and potential applications. Nat Rev Drug Discov 2002, 1(9): 674-82.
77. Rotella, D.P. Phosphodiesterases type 5 inhibitors: Discovery and theapeutic utility. Drugs Future 2001, 26(2): 153-62.
78. Ahn, H.-S., Bercovici, A., Boykow, G. et al. Potent tetracyclic guanine inhibitors of PDE 1 and PDE 5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity. J Med Chem 1997, 40: 2196-210.
79. Watanabe, N., Adachi, H., Takase, Y. et al. 4-(3-Chloro-4-methoxybenzyl) aminophthalazines: Synthesis and inhibitory activity toward phosphodiesterase 5. J Med Chem 2000, 43: 2523-9.
80. Rotella, D.P., Sun, Z., Zhu, Y. et al. N-3-Substituted imidazoquinazolinones: Potent and selective PDE 5 inhibitors as potential agents for the treatment of erectile dysfunction. J Med Chem 2000, 43: 1257-63.
81. Hosogai, N., Hamada, K., Tomita, M. et al. FR226807: A potent and selective PDE5 inhibitor. Eur J Pharmacol 2001, 428: 295-302.
82. Marks, L.S. Erectile dysfunction (ED) update, 2003-Viagra vs the new PDE-5 inhibitors: Levitra and Cialis. Medical Director, USRF 2003, 1-3.
83. Junqing, G., Barbosa, J., John, P.W., Quesnella, C. Preparation of pyrimidine inhibitors of PDE 7. Int Pat Appl WO 02 102 313 (Chem Abstr 2003, 138: 55972).
84. Pitts, W. J., Barbosa, J. Preparation of quinazoline and pyrido-[2,3-d]-pyrimidine inhibitors of PDE 7. Int Pat Appl WO 02 102 315 (Chem Abstr 2003, 138: 55973).
85. Paul, D.M., Bernadette, H., Ian, M.K., Michael, J. Preparation of pyrazolo-[4,3-d]-pyrimidin-7-ones as PDE 9 inhibitors for treating cardiovascular disorders. PCT. Int Pat Appl WO 03 37899 (Chem Abstr 2003, 138: 368907).
86. Soderling, S.H., Bayuga, S.J., Beavo, J.A. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 1998, 273(25): 15553-8.
87. Ergueden, J.K., Marcus, B., Mills, B., Dietmar, F. Preparation of imidazotriazines as PDE 10A inhibitors for treatment of neurodegenerative diseases. Int Pat Appl WO 03 693 (Chem Abstr 2003, 138: 73278).
88. Lebel, L.A., Menniti, F.S., Schmidt, C.J. Selective PDE 10 inhibitors for the treatment of neurological and psychiatric disorders and compound identification method. US Pat Appl Publ 18,047 (Chem Abstr 2003, 138: 83407).